MTOR, mechanistic target of rapamycin kinase, 2475

N. diseases: 960; N. variants: 48
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.400 Biomarker disease CTD_human Identification of recurrent fusion genes across multiple cancer types. 30705370 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.400 Biomarker disease BEFREE Upregulation of DEPTOR is a positive prognostic marker in ovarian cancer and is increased in response to mTOR pathway inhibition suggesting that it functions as a tumour suppressor gene in endometrioid ovarian carcinoma. 30387804 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.400 Biomarker disease BEFREE Mammalian target of rapamycin (mTOR) siRNA (simTOR) co-transfection was performed to verify the role of mTOR in the suppression effect of miR-1271 on ovarian cancer. 31411791 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.400 Biomarker disease BEFREE Likewise, the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway is also a central regulator of the ovarian cancer. 29401696 2018
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.400 Biomarker disease BEFREE The mechanistic target of rapamycin (mTOR) level is hyperelevated in a number of tumor types, including ovarian cancer. 30272366 2018
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.400 Biomarker disease BEFREE Sphere forming cells (multicellular spheroids) present in malignant ascites of patients with ovarian cancer represent a major impediment to effective treatment. p70 S6 kinase (p70S6K), which is a downstream effector of mammalian target of rapamycin, is frequently hyperactivated in human ovarian cancer. 25193855 2014
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.400 Biomarker disease BEFREE The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. 23591839 2013
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.400 AlteredExpression disease BEFREE Our results indicate that there are significant differences in the expression of some of the mTOR-related tumor suppressors and oncogenes which could be associated with the pathogenesis of ovarian cancer. 21744334 2011
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.400 Biomarker disease CTD_human Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells. 20138251 2010
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.400 Biomarker disease BEFREE A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. 20081105 2010
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.400 Biomarker disease LHGDN Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. 19020722 2008
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.400 AlteredExpression disease LHGDN These results indicate that PI3K mediates G(1) progression and cyclin expression through activation of an AKT/mTOR/p70S6K1 signaling pathway in the ovarian cancer cells. 15028555 2004